Oncotarget

Research Papers:

RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells

Ruey-Shyang Soong, Ravi K. Anchoori, Benjamin Yang, Andrew Yang, Ssu-Hsueh Tseng, Liangmei He, Ya-Chea Tsai, Chien-Fu Hung, _ Chien-Fu Hung _

PDF |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:68489-68502. https://doi.org/10.18632/oncotarget.12095

Metrics: PDF 511 views  |   HTML 446 views  |   ?  


Abstract

Ruey-Shyang Soong1,5,6, Ravi K. Anchoori4, Benjamin Yang1, Andrew Yang1, Ssu-Hsueh Tseng1, Liangmei He1, Ya-Chea Tsai1, Richard B.S. Roden1,2,4, Chien-Fu Hung1,4

1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States

2Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, MD, United States

3Department of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, MD, United States

4Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States

5Department of General Surgery, Chang Gung Memorial Hospital at Keelung, Keelung City, Taiwan

6Department of Chang Gung University, College of Medicine, Taoyuan, Taiwan

Correspondence to:

Chien-Fu Hung, email: chung2@jhmi.edu

Keywords: RPN13, proteasome, immunosuppression, MDSCs, Stat3

Received: January 14, 2016     Accepted: September 12, 2016     Published: September 17, 2016

ABSTRACT

Myeloid-derived-suppressor cells (MDSCs) are key mediators of immune suppression in the ovarian tumor microenvironment. Modulation of MDSC function to relieve immunosuppression may enhance the immunologic clearance of tumors. The bis-benzylidine piperidone RA190 binds to the ubiquitin receptor RPN13/ADRM1 on the 19S regulatory particle of the proteasome and directly kills ovarian cancer cells by triggering proteotoxic stress. Here we examine the effect of RA190 treatment on the immunosuppression induced by MDSCs in the tumor microenvironment, specifically on the immunosuppression induced by MDSCs. We show that RA190 reduces the expression of Stat3 and the levels of key immunosuppressive enzymes and cytokines arginase, iNOS, and IL-10 in MDSCs, while boosting expression of the immunostimulatory cytokine IL-12. Furthermore, we show that the RA190-treated MDSCs lost their capacity to suppress CD8+ T cell function. Finally, we show that RA190 treatment of mice bearing syngeneic ovarian tumor elicits potent CD8+ T cell antitumor immune responses and improves tumor control and survival. These data suggest the potential of RA190 for ovarian cancer treatment by both direct killing of tumor cells via proteasome inhibition and relief of MDSC-mediated suppression of CD8 T cell-dependent antitumor immunity elicited by the apoptotic tumor cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12095